Correlation between CA-125 and Ovarian Cancer: A Bangladesh Perspective

DOI: https://doi.org/10.47648/jmsr.2005.v0502.02

Siddique S F 1 , Chowdhury T A2 , Hai M A3 , Akter P S4 , Rahman Md A5

Abstract

CA-125 is an important tumour associated antigen for ovarian cancer diagnosing and assessing the prognosis of the patient. The rate at ',Mich CA-125 levels change is of an indirect measure of the level of cancer growth and inflammation in our body. This paper aims at evaluating the correlation between ovarian cance, its treatment and CA-125 level. A multicenter prospective study on oixtriart malignancy was do.ne. The study team included gynaecologists, oncologists. allistopathologists and an oncology associate from the company (Sarrofi-Aventis)supplying the drugs. The patiems were enrolled during 1999 to 2002 and have been followed up till now The level of CA-125 was done front one single idendfied laboratory for making the result standard. Seventeen patients with different stages and opes of ovarfint cancer were enrolled in the study. CA-125 level was assessed prior to treatment, at the end of chemotherapy and in the subsequent follow up. Disease status following chemotherapy was also evaluated. When the chemotherapy started, the level of CA-125 started declining in 13 patients and came down, to 50% of the previous value at the end of second cycle. The CA-125 level came down to less than 35 U/wI after the end of 3-6 cycles of chemotherapy (normal value is 35 UMW. and this level came down to less than 10 Ulm! in all 13 patinas who survived. The decline rate of CA-I25 after chemotherapy was 77%. All those patients are found to be clinically disease free and physically well all now. The three year survival rate is 72%. Toxicity profile was also acceprabk. CA-125 level is an important investigation for diagnosing ovarian cancer. But the rate of decline of the level of CA-125 following treatment is an important prognostic factor. Tim chemotherapy used in the study was a combination of Taxotere and Carboplatin.

Keywords:


  1. Assistant Professor, Department of Obstetrics and Gynecology

    Holy Family Red Crescent Medical College, Dhaka

  2. Professor, Department of Obstetrics and Gynecology

    BIRDEM

  3. Ahsania Mission Cancer Hospital

  4. Dhaka Medical College Hospital

  5. Sanofi-Aventis Oncology


Volume 5, Number 2 July 2005
Page: 45150